GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
Executive Summary
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
You may also be interested in...
Genzyme Cerezyme Medicare Outpatient Payment Set At 94% Of AWP
Genzyme's Cerezyme and Ceredase will be reimbursed at 94% of average wholesale price under the final rule for 2004 reimbursement within the Medicare Hospital Outpatient Prospective Payment System
Genzyme Cerezyme Medicare Outpatient Payment Set At 94% Of AWP
Genzyme's Cerezyme and Ceredase will be reimbursed at 94% of average wholesale price under the final rule for 2004 reimbursement within the Medicare Hospital Outpatient Prospective Payment System
GSK Bexxar Launch Aims To Train 200 Sites By Year-End; AWP Is $32,500
GlaxoSmithKline and Corixa's launch plan for Bexxar will have more than half of the 350 radiopharmacies in the U.S. trained to administer the non-Hodgkin's lymphoma treatment by year-end